接受造血干细胞移植的儿科患者可从新型每日一次静脉白消安给药列线图中极大获益
本研究基于137例儿科患者(年龄0.6-22.2岁)的2183个白消安浓度,建立群体药代动力学模型并推导每日一次静脉白消安给药列线图。模拟显示新列线图使>60%患者达到目标AUC,同时毒性AUC水平超标患者<25%,优于FDA方案、EMA方案及未做治疗药物监测的经验性每日一次方案。
要点
- 基于137例儿科患者2183个浓度建立群体药代动力学模型并推导每日一次静脉白消安给药列线图。
- 新列线图模拟中>60%患者达到每日目标AUC,毒性AUC超标患者<25%。
- 新列线图表现显著优于FDA方案、EMA方案及未做治疗药物监测的经验性每日一次方案。
核心结论
- 新型每日一次静脉白消安给药列线图对接受造血干细胞移植的儿科患者有用,尤其在治疗药物监测服务不易获得时或用于优化第1天剂量。
研究设计与样本
- 使用137例接受每日一次静脉白消安4天后行造血干细胞移植的儿科患者(年龄0.6-22.2岁)的2183个白消安浓度进行群体药代动力学分析,并基于最终模型推导每日一次静脉白消安给药列线图。
主要发现
- 含体表面积、年龄、给药天数及天冬氨酸氨基转移酶为显著协变量的单室开放线性药代动力学模型充分描述了白消安的浓度-时间曲线。
- 基于药代动力学模型的最优给药列线图表现显著优于其他给药方案,在整个治疗期间使>60%患者达到目标AUC,同时毒性AUC水平超标患者<25%。
关键数值与推荐
- 模拟患者中,新列线图使>60%患者达到每日目标AUC,毒性AUC水平超标患者<25%。
临床怎么用
- 作者认为新型每日一次白消安给药列线图对临床医生有用,尤其在治疗药物监测服务不易获得时或用于优化第1天剂量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Busulfan, a bifunctional alkylating agent, has been used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT). The aim of this study was to derive a novel once-daily intravenous (IV) busulfan dosing nomogram for pediatric patients undergoing HSCT using a population pharmacokinetic (PK) model. A population PK analysis was performed using 2183 busulfan concentrations in 137 pediatric patients (age: 0.6-22.2 years), who received IV busulfan once-daily for 4 days before undergoing HSCT. Based on the final population PK model, an optimal once-daily IV busulfan dosing nomogram was derived. The percentage of simulated patients achieving the daily target area under the concentration-time curve (AUC) by the new nomogram was compared with that by other busulfan dosing regimens including the FDA regimen, the EMA regimen, and the empirical once-daily regimen without therapeutic drug monitoring (TDM). A one-compartment open linear PK model incorporating patient's body surface area, age, dosing day, and aspartate aminotransferase as a significant covariate adequately described the concentration-time profiles of busulfan. An optimal dosing nomogram based on the PK model performed significantly better than the other dosing regimens, resulting in >60% of patients achieving the target AUC while the percentage of patients exceeding the toxic AUC level was kept <25% during the entire treatment period. A novel once-daily busulfan dosing nomogram for pediatric patients undergoing HSCT is useful for clinicians, particularly in a setting where TDM service is not readily available or to optimize the dose on day 1.
引用
- Rhee SJ, Lee JW, Yu KS, et al. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. Am J Hematol. 2017. PMID: 28370238. doi:10.1002/ajh.24734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。